Find and Join

News Logo

• Those Lilly letters

  We learned this week that several compounding pharmacies have received a cease-and-desist letter from a law firm representing Eli Lilly. read more →

• CCH registration is OPEN!

  Demonstrate your commitment to your patients and practice at APC’s annual DC fly-in for pharmacy compounders, September 17-18 at Hilton National Mall. read more →

• Demonstrably difficult list, demonstrably problematic

  The FDA is proposing a rule that would add categories to both the 503A and 503B demonstrably difficult to compound (DDC) lists — a plan that has a host of issues. read more →

• APC to CA BOP: How does this make patients safer?

  The California Board of Pharmacy has proposed several new regulations for pharmacy compounding, some of which, to put it bluntly (and we did put it bluntly), are not rooted in science or evidence. read more →

• Truth and GLP-1s

  Compounded GLP-1 drugs. Perhaps you’ve heard about them? read more →

• When media does its job

  Well check this out: A news story about compounded GLP-1s that’s actually accurate, sans all the usual hand-wringing and fear-mongering. read more →

More News

Fagron Ad

Blank

PCCA Ad

Blank

Medisca Ad

Blank

TopiClick Ad

Blank

Wedgewood Ad

In comments submitted earlier this week, APC took issue with provisions of proposed new compounding regulations from the California Board of Pharmacy.

“We have serious concerns about the Board’s proposed regulations and the ongoing failure of the Board to root its regulation and enforcement of compounding in applicable law and science,” the letter states.

In addition to a cover letter enunciating five broad concerns about the Board’s proposal and its oversight of compounding in general, APC submitted detailed comments on specific provisions of the proposal. 

During the board’s public hearing on June 18, 2024, APC’s Tenille Davis will present the association’s concerns. Members and licensees in the state of California are urged to register to attend either virtually or in person. Details here.